Abiopharma

🔍 Burns Thomas William (Executive)

Company: GLAUKOS Corp (GKOS)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Sold 2,744 shares of Common Stock at $105.23 per share (Direct)
  Date: 2026-03-24 | Code: F | equity_swap_involved: 0 | shares_owned_after: 239,707.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: Through the Burns Family Trust | shares_owned_after: 961,285.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: Through the Burns Annuity Trust | shares_owned_after: 238,107.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: Through the Burns Charitable Remainder Trust | shares_owned_after: 120,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: Through the Thomas W. Burns Irrevocable Trust | shares_owned_after: 100,000.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | nature_of_ownership: Through the Janet M. Burns Irrevocable Trust | shares_owned_after: 100,000.00

Footnotes:

• F1: Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock underlying restricted stock units previously granted by the Issuer on March 24, 2022.
• F2: Includes 59,399 restricted stock units that have not yet vested or been delivered to the Reporting Person.